• Resources
  • Case Studies
  • Licensing strategy for new qPCR assay to determine in-vitro cell contamination & cell-type verification


A leading UK University was developing a ‘3-in-1’ PCR-based assay for rapid cell line verification and purity testing. The technology comprised a PCR-based assay containing novel markers for rapid, cost-effective human cell identification and validation, including STR genotyping and rodent/mycoplasma contamination testing.  The University was keen to progress with commercial engagement with a view to concluding a licensing agreement and required evidence-based guidance on the strategy and the next steps to achieving these goals, specifically including the following:

  • Develop the value proposition for the technology and turn it into a pitch document to be used with prospective licensees/collaborators
  • Develop a licensing strategy/plan including a plan for commercial engagement
  • Provide support to licensing negotiations.  


Alacrita's consultants met with the Principal Investigator and proceeded to develop a licensing strategy & plan, including:

  • Establishing the development status of the technology and reviewing commercialization efforts to date
  • Confirming technology value proposition in key market applications and commercial exploitation model
  • Developing non-confidential and confidential pitch documents
  • Compiling a database of prospective licensees
  • Developing a licensing strategy & plan

The pitch documents were successfully used to engage potential collaborators and interest was generated for partnership.


Related Case Studies